|
SOPHEON PLC
("Sopheon" or the "Company")
Issue of Equity
Sopheon, the InnovationOps software company, announces that following the exercise of options by a former employee it has allotted 13,726 new Ordinary Shares of
Application will be made for the new Ordinary Shares to be admitted to trading on AIM and dealings are expected to commence on 12 January 2024.
The new Ordinary Shares will rank pari passu with the Company's existing Ordinary Shares. The total number of Ordinary Shares in issue following Admission will be 10,706,805. The Company does not hold any shares in treasury. Accordingly, the figure of 10,706,805 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FCA's Disclosure Guidance and Transparency Rules.
In accordance with Rule 2.9 of the City Code on Takeovers and Mergers (the "Code"), the Company confirms, pursuant to the exercise of options that there are currently 10,706,805 new Ordinary Shares of
For further information contact:
Andy Michuda (Executive Chairman) |
Sopheon plc |
+ 44 (0) 1276 919 560 |
Carl Holmes/Abigail Kelly / George Dollemore (Corporate Finance) Sunila de Silva (ECM) |
Cavendish Capital Markets Ltd |
+ 44 (0) 20 7220 0500 |
About Sopheon. Sopheon (LSE: SPE) empowers organizations to change the world while achieving exceptional long-term revenue growth and profitability. By operationalizing the entire innovation life cycle, Accolade® and Acclaim™ software and expertise enable innovation, product and project professionals to accomplish the full range of InnovationOps tasks to drive innovation at scale. Sopheon's industry leadership was highlighted in the comprehensive MarketsandMarkets™ report on the Innovation Management market, in which Sopheon was listed in the "Stars" category, the highest recognition. Sopheon's solutions have been implemented by hundreds of blue-chip customers with over 125,000 users in 50 countries. Sopheon is listed on the AIM Market of the London Stock Exchange. For more information, please visit www.sopheon.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.